Fagron strengthens its market positioning with the acquisitions
of CareFirst in North America and Injeplast in Brazil
NEWS 7 Jan 2025
Fagron strengthens its market positioning with the acquisitions
of CareFirst in North America and Injeplast in Brazil
Fagron, the leading global player in pharmaceutical compounding
is pleased to announce the signing of two strategic acquisitions:
CareFirst Specialty Pharmacy in North America and Injeplast in
Brazil. These acquisitions underscore Fagron’s commitment to
expanding across our key markets whilst adhering to our
disciplined acquisition strategy.
The combined enterprise value of these two acquisitions is
c.€30m and are fully financed through Fagron’s own resources and
remain subject to customary clearances. Both businesses operate
with an EBITDA margin slightly above Fagron’s existing group
margin.
CareFirst Specialty Pharmacy, based in New Jersey, USA, is a
503A pharmaceutical compounder specializing in the health &
wellness sector. It provides non-sterile medication through
patient-specific prescriptions, with a particular focus on
hormone replacement therapy and dermatology.
With mid-single digit (€m) in annual revenue, Carefirst enhances
Fagron’s footprint in North America’s prevention and lifestyle
markets. This acquisition enables Fagron to meet increasing
demand for personalized healthcare solutions and reinforces its
leadership in this growing segment.
Injeplast, located in São Paulo, Brazil, is a GMP-certified,
vertically integrated producer of plastic packaging. With low
double digit (€m) in annual revenue, the company offers
high-quality packaging solutions and efficient manufacturing
processes.
This acquisition supports Fagron’s Essentials strategy by
broadening its product portfolio and customer base in Latin
America. Additionally, Injeplast’s capabilities will extend
Fagron’s support to other regions, further enhancing global
operations.
In addition, the EuroOTC acquisition announced during Q3 2024
trading update has now closed.
Rafael Padilla, CEO of Fagron commented: “We are incredibly
pleased to announce these two acquisitions, which reflect our
disciplined and strategic growth approach. The acquisition of
CareFirst allows us to meet the increasing demand in the
prevention and lifestyle segments, reinforcing our leadership in
North America. Similarly, the addition of Injeplast will
strengthen our market positioning in Latin America by broadening
our product portfolio and expanding our customer base. Both
businesses align with Fagron’s Group margin, and we expect to
integrate them over the next 18 to 24 months.”
Further information
Karin de Jong
Chief Financial Officer
investors@fagron.com
About Fagron
Fagron is a leading global company active in pharmaceutical
compounding, focusing on delivering personalized medicine to
hospitals, pharmacies, clinics and patients in more than 30
countries around the world.
Belgian company Fagron NV has its registered office in Nazareth
and is listed on Euronext Brussels and Euronext Amsterdam under
the ticker symbol ‘FAGR’. Fagron’s operational activities are
managed by the Dutch company Fagron BV, which is headquartered in
Rotterdam.
The M&A market for healthcare companies continues to build on STRATEGIC opportunities and a fragmented market. Consolidations along with unprecedented demand are driving scale across the continuum of care. The strategic corporate buyers and private equity investors remain committed to acquiring strong businesses that are well prepared for a transaction. Across the continuum of care, these buyers and investors are looking for well established, profitable businesses and offering prime valuations and options for management.
Do you know the current market value of your business? We do! We are here to help you plan, prepare, explore and succeed in executing your strategic options.
Contact Paragon Ventures for more information.
800-719-1555
